News | December 31, 2014

Transcatheter Technologies Expands Platform with Transfemoral System

Product will complement Trinity TAVI

Heart valve repair, Trinity Transapical TAVI system

Image courtesy of Transcatheter Technologies GmBH


December 31, 2014 — Transcatheter Technologies GmbH announced that it has expanded the Trinity technology platform to include a transfemoral version.

In September 2014, Transcatheter Technologies disclosed the one year follow up results of its Trinity transapical TAVI system. Unlike currently marketed TAVI systems, the Trinity aortic valve can be positioned or even repositioned after a full implantation in a safe manner. Trinity’s sealing cuff provides results without PVL, a well-known and frequent complication of TAVI. The risk of atrio-ventricular (AV) block has been essentially alleviated because of the supra-annular anchoring of the Trinity valve.

For more information: www.transcatheter-technologies.com/home.html


Additional Content

News | Heart Valve Technology

Oct. 29, 2026 — Abbott has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its ...

Home November 05, 2026
Home
News | Heart Valve Technology

Oct. 21, 2026 — Edwards Lifesciences Corp. recently announced that the U.S. Food and Drug Administration (FDA) has ...

Home October 23, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Following transcatheter aortic valve implantation (TAVI), disturbances in the heart’s electrical ...

Home September 25, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai have received a $3.6 million, four-year ...

Home September 24, 2026
Home
News | Heart Valve Technology

June 29, 2026 — Laplace Interventional recently announced that the U.S. Food and Drug Administration (FDA) has approved ...

Home July 02, 2026
Home
Subscribe Now